Kyntra Bio Inc KYNB
6.94
(0.06)
(0.86%)
as of 25 Sep
- Market cap
- $28.3M
- P/E
- 0.2×
Follow KYNB
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(189.86%) | (165.18%) | (144.04%) | (157.83%) | |
| 107.44% | 109.81% | 119.06% | 131.26% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
221.30% | 262.71% | 223.39% | 301.38% | |
Average Days of Receivables |
5.32 | 12.24 | 247.29 | 27.43 | |
Free Cash Flow per Share |
(4.18) | (1.19) | (5.28) | (9.40) | |
Free Cash Flow |
(16.88) | (4.81) | (21.38) | (38.05) | |
Capital Expenditures |
0.03 | (0.04) | — | — | |
Piotroski F-Score |
6.00 | 5.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(14.84%) | (6.63%) | (37.86%) | (61.68%) | |
Accounts Receivable Turnover |
0.57 | 18.48 | 2.87 | 19.12 | |
Accounts Payable Turnover |
(0.78) | 0.13 | 0.71 | 0.48 | |
Inventory Turnover |
(0.40) | 0.16 | 1.35 | 1.19 | |
Average Days of Payables |
(333.86) | 2,458.50 | 421.61 | 633.50 | |
Days of Inventory on Hand |
(253.30) | 2,457.19 | 280.08 | 285.45 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
278.56% | 365.17% | 294.50% | 495.21% | |
Selling, General and Administrative Expense of Revenue |
347.10% | 430.26% | 342.32% | 599.39% | |
Share Based Compensation of Revenue |
67.06% | 102.11% | 65.53% | 86.33% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.08) | (0.03) | (0.13) | (0.21) | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.02 | (0.06) | 0.00 | 0.00 | |
Revenue per Share |
2.05 | 1.59 | 1.84 | 1.14 | |
Operating CF per Share |
(4.18) | (1.18) | (5.28) | (9.40) | |
Capex per Share |
0.01 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Net Profit Margin |
2,598.55% | 2,848.63% | 2,199.42% | 3,967.77% |
Columns are period end dates